Lb Pharmaceuticals Inc.

This study tests a new drug, LB 102, to see if it helps reduce schizophrenia symptoms better than a placebo. About 456 adults with acute schizophrenia will take either the drug or a placebo for 6 weeks while staying in the hospital. The main goal is to measure changes in symptoms…

This study is testing the long-term safety of a new medication called LB-102 for adults with stable schizophrenia. About 900 participants will take the drug for 52 weeks to see what side effects occur. The goal is to make sure the drug is safe enough for ongoing use to control sc…

This Phase 2 study tests whether LB-102 can reduce depressive symptoms in adults with bipolar I disorder who are currently in a major depressive episode. About 320 participants will receive either the drug or a placebo for 6 weeks. The main goal is to see if LB-102 improves depre…